Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term double-blind extension of tadalafil in pulmonary arterial hypertension
2005-002844-24Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tadalafil in pulmonary arterial hypertension (PAH) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Six-minute walk distance change and Time to WHO functional class deterioration. Started Sep 2005; status: completed.
02
Drugs
tadalafil
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2005-002844-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-002844-24.